Aberrant Localization of the Neuronal Class III b-Tubulin in Astrocytomas A Marker for Anaplastic Potential

c Background.—The class III b-tubulin isotype (bIII) is widely regarded as a neuronal marker in development and neoplasia. In previous work, we have shown that the expression of bIII in neuronal/neuroblastic tumors is differentiation dependent. In contrast, the aberrant localization of this isotype in certain nonneuronal neoplasms, such as epithelial neuroendocrine lung tumors, is associated with anaplastic potential. Objective.—To test the generality of this observation, we investigated the immunoreactivity profile of bIII in astrocytomas. Design.—Sixty archival, surgically excised astrocytomas (8 pilocytic astrocytomas, WHO grade 1; 18 diffuse fibrillary astrocytomas, WHO grade 2; 4 anaplastic astrocytomas, WHO grade 3; and 30 glioblastomas, WHO grade 4), were studied by immunohistochemistry using anti-bIII monoclonal (TuJ1) and polyclonal antibodies. A monoclonal antibody to Ki-67 nuclear antigen (NC-MM1) was used as a marker for cell proliferation. Antibodies to glial fibrillary acidic protein (GFAP) and BM89 synaptic vesicle antigen/synaptophysin were used as glial and neuronal markers, respectively. Results.—The bIII immunoreactivity was significantly greater in high-grade astrocytomas (anaplastic astrocytomas and glioblastomas; median labeling index [MLI], 35%; interquartile range [IQR], 20%‐47%) as compared with diffuse fibrillary astrocytomas (MLI, 4%; IQR, 0.2%‐21%) (P , .0001) and was rarely detectable in pilocytic astrocytomas (MLI, 0%; IQR, 0%‐0.5%) (P , .0001 vs high-grade astrocytomas; P , .01 vs diffuse fibrillary astrocytomas). A highly significant, grade-dependent relationship was observed between bIII and Ki-67 labeling and malignancy, but this association was stronger for Ki-67 than for bIII (bIII, P , .006; Ki-67, P , .0001). There was co-localization of bIII and GFAP in neoplastic astrocytes, but no BM89 synaptic vesicle antigen/synaptophysin staining was detected. Conclusions.—In the context of astrocytic gliomas, bIII immunoreactivity is associated with an ascending gradient of malignancy and thus may be a useful ancillary diagnostic marker. However, the significance of bIII-positive phenotypes in diffuse fibrillary astrocytomas with respect to prognostic and predictive value requires further evaluation. Under certain neoplastic conditions, bIII expression is not neuron specific, calling for a cautious interpretation of bIII-positive phenotypes in brain tumors. (Arch Pathol Lab Med. 2001;125:613‐624)

[1]  A. Frankfurter,et al.  Differential distribution of the neuron-associated class III beta-tubulin in neuroendocrine lung tumors. , 2009, Archives of pathology & laboratory medicine.

[2]  J. Kleinman,et al.  Localization of epidermal growth factor receptors and putative neuroblasts in human subependymal zone , 2000, The Journal of comparative neurology.

[3]  E. Nogales,et al.  A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  P. Burger,et al.  Pediatric astrocytomas with monomorphous pilomyxoid features and a less favorable outcome. , 1999, Journal of neuropathology and experimental neurology.

[5]  M. Kavallaris,et al.  Antisense oligonucleotides to class III β-tubulin sensitize drug-resistant cells to Taxol , 1999, British Journal of Cancer.

[6]  D. Schiffer,et al.  Cell-cycle inhibitor p27/Kip-1 expression in non-astrocytic and non-oligodendrocytic human nervous system tumors , 1999, Neuroscience Letters.

[7]  M. Strawderman,et al.  MIB-1 Proliferation Index Predicts Survival among Patients with Grade II Astrocytoma , 1998, Journal of neuropathology and experimental neurology.

[8]  H. Choy,et al.  Histologic evidence of a radiosensitizing effect of Taxol in patients with astrocytomas , 1998, Journal of Neuro-Oncology.

[9]  Anderson,et al.  Expression of neuronal markers in oligodendrogliomas: an immunohistochemical study , 1998, Neuropathology and applied neurobiology.

[10]  M. Berger,et al.  Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Korf,et al.  Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases , 1998, Acta Neuropathologica.

[12]  A. Frankfurter,et al.  Class III β‐Tubulin isotype (β III) in the adrenal medulla: II. Localization in primary human pheochromocytomas , 1998 .

[13]  A. Frankfurter,et al.  Class III β‐Tubulin isotype (β III) in the adrenal medulla: I. Localization in the developing human adrenal medulla , 1998 .

[14]  G. Hudes,et al.  Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. , 1998, British Journal of Cancer.

[15]  G. Hudes,et al.  Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents. , 1998, Biochimica et biophysica acta.

[16]  M. Luskin,et al.  Neuronal Progenitor Cells Derived from the Anterior Subventricular Zone of the Neonatal Rat Forebrain Continue to Proliferatein Vitroand Express a Neuronal Phenotype , 1997, Molecular and Cellular Neuroscience.

[17]  A. Fasolo,et al.  Glial Tubes in the Rostral Migratory Stream of the Adult Rat , 1997, Brain Research Bulletin.

[18]  R. Yeung,et al.  Subependymal astrocytic hamartomas in the Eker rat model of tuberous sclerosis. , 1997, The American journal of pathology.

[19]  I. Blümcke,et al.  Neural antigens in oligodendrogliomas and dysembryoplastic neuroepithelial tumors , 1997, Acta Neuropathologica.

[20]  M. Kavallaris,et al.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. , 1997, The Journal of clinical investigation.

[21]  S. Torp,et al.  Proliferative activity in human glioblastomas: evaluation of different Ki67 equivalent antibodies. , 1997, Molecular pathology : MP.

[22]  J. García-Verdugo,et al.  Cellular Composition and Three-Dimensional Organization of the Subventricular Germinal Zone in the Adult Mammalian Brain , 1997, The Journal of Neuroscience.

[23]  D. Ross,et al.  A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. , 1997, Journal of neuropathology and experimental neurology.

[24]  A. Mamalaki,et al.  Purification and cDNA cloning of mouse BM89 antigen shows that it is identical with the synaptic vesicle protein synaptophysin , 1997, Journal of neuroscience research.

[25]  W. B. Derry,et al.  Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. , 1997, Biochemistry.

[26]  S. Vandenberg,et al.  Ganglioglioma: an ultrastructural and immunohistochemical study. , 1997, Cancer.

[27]  Y. Nakazato,et al.  Pale islands in medulloblastoma consist of differentiated cells with low growth potential , 1997, Pathology international.

[28]  D. Schiffer.  Brain Tumors: Biology, Pathology and Clinical References , 1996 .

[29]  M. Berger,et al.  Phase II study of paclitaxel in patients with recurrent malignant glioma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Louis,et al.  Use of MIB‐1 (Ki‐67) Immunoreactivity in Differentiating Grade II and Grade III Gliomas , 1996, Journal of neuropathology and experimental neurology.

[31]  R. Luduena,et al.  Phosphorylation of III -Tubulin , 1996 .

[32]  D. Steindler,et al.  Cell and molecular analysis of the developing and adult mouse subventricular zone of the cerebral hemispheres , 1995, The Journal of comparative neurology.

[33]  D. Ellison,et al.  Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[34]  A. Frankfurter,et al.  A cytomorphological scheme of differentiating neuronal phenotypes in cerebellar medulloblastomas based on immunolocalization of class III beta-tubulin isotype (beta III) and proliferating cell nuclear antigen (PCNA)/cyclin. , 1995, Clinical neuropathology.

[35]  C. Katsetos,et al.  Lobar pilocytic astrocytomas of the cerebral hemispheres: I. Diagnosis and nosology. , 1994, Clinical neuropathology.

[36]  M B Luskin,et al.  Expression of neuron-specific tubulin defines a novel population in the proliferative layers of the developing telencephalon , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[37]  A. Frankfurter,et al.  Neuron-associated class III β-tubulin, tau, and MAP2 in the D-283 Med cell line and in primary explants of human medulloblastoma , 1994, The Histochemical Journal.

[38]  A. Frankfurter,et al.  The stromal Schwann cell during maturation of peripheral neuroblastomas. Immunohistochemical observations with antibodies to the neuronal class III beta-tubulin isotype (beta III) and S-100 protein. , 1994, Clinical neuropathology.

[39]  A. Frankfurter,et al.  Differential Localization of Class III β‐Tubulin Isotype and Calbindin‐D28k Defines Distinct Neuronal Types in the Developing Human Cerebellar Cortex , 1993, Journal of neuropathology and experimental neurology.

[40]  M. Jordan,et al.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A. Frankfurter,et al.  Absence of neuron‐associated microtubule proteins in the rat C‐6 glioma cell line. A comparative immunoblot and imrnunohistochemical study , 1993, Neuropathology and applied neurobiology.

[42]  R. Luduena,et al.  Removal of beta III isotype enhances taxol induced microtubule assembly. , 1993, Cell structure and function.

[43]  J. Trojanowski,et al.  Co-expression of low molecular weight neurofilament protein and glial fibrillary acidic protein in established human glioma cell lines. , 1993, The American journal of pathology.

[44]  A. Frankfurter,et al.  Initial tract formation in the mouse brain , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[45]  A. Frankfurter,et al.  The presence of neuron-associated microtubule proteins in the human U-251 MG cell line. A comparative immunoblot and immunohistochemical study. , 1992, Molecular and chemical neuropathology.

[46]  S. Vandenberg,et al.  Cytoskeletal Immunohistochemistry of Central Neurocytomas , 1992, The American journal of surgical pathology.

[47]  R. Matsas,et al.  Monoclonal antibody BM89 recognizes a novel cell surface glycoprotein of the L2/HNK-1 family in the developing mammalian nervous system , 1992, Neuroscience.

[48]  F. Gilles,et al.  Co-expression of four intermediate filament subclasses in childhood glial neoplasms. , 1991, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[49]  M. Osborn,et al.  Unexpected immunoreactivities of intermediate filament antibodies in human brain and brain tumors. , 1991, The American journal of pathology.

[50]  A. Frankfurter,et al.  Characterization of posttranslational modifications in neuron-specific class III beta-tubulin by mass spectrometry. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[52]  H. Frierson,et al.  Olfactory neuroblastoma. Additional immunohistochemical characterization. , 1990, American journal of clinical pathology.

[53]  A. Frankfurter,et al.  Posttranslational modification of class III beta-tubulin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[54]  D. Miller,et al.  Synaptophysin: a sensitive and specific marker for ganglion cells in central nervous system neoplasms. , 1990, Human pathology.

[55]  A. Frankfurter,et al.  Cerebellar desmoplastic medulloblastomas. A further immunohistochemical characterization of the reticulin-free pale islands. , 1989, Archives of pathology & laboratory medicine.

[56]  A. Frankfurter,et al.  Development of the peripheral trigeminal system in the chick revealed by an isotype‐specific anti‐beta‐tubulin monoclonal antibody , 1989, The Journal of comparative neurology.

[57]  K. Sullivan,et al.  Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[58]  L. J. Rubinstein,et al.  Tumours of the central nervous system , 1979, Oxford Desk Reference: Oncology.

[59]  D. Troost,et al.  5-Year survival and clinical prognostic factors in progressive supratentorial diffuse “low-grade” astrocytoma: A retrospective analysis of 46 cases , 2005, Acta Neurochirurgica.

[60]  A. Frankfurter,et al.  Neuron-associated class III β-tubulin isotype, retinal S-antigen, synaptophysin, and glial fibrillary acidic protein in human medulloblastomas: a clinicopathological analysis of 36 cases , 2004, Acta Neuropathologica.

[61]  A. Chiò,et al.  Tumor cell proliferation and apoptosis in medulloblastoma , 2004, Acta Neuropathologica.

[62]  A. Sehgal,et al.  Molecular changes during the genesis of human gliomas. , 1998, Seminars in surgical oncology.

[63]  R. Luduena.  Multiple forms of tubulin: different gene products and covalent modifications. , 1998, International review of cytology.

[64]  I. Vajtai,et al.  Pleomorphic xanthoastrocytoma with gangliogliomatous component. , 1997, Pathology, research and practice.

[65]  S. Vandenberg,et al.  Immunohistochemical characterization of subependymal giant cell astrocytomas , 1996, Acta Neuropathologica.

[66]  L. Rorke,et al.  Divergent differentiation in pleomorphic xanthoastrocytoma. Evidence for a neuronal element and possible relationship to ganglion cell tumors. , 1996, The American journal of surgical pathology.

[67]  A. Frankfurter,et al.  Neuron-associated class III beta-tubulin isotype, microtubule-associated protein 2, and synaptophysin in human retinoblastomas in situ. Further immunohistochemical observations on the Flexner-Wintersteiner rosettes. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[68]  A. Frankfurter,et al.  Antigenic Expression of Neuron-Associated Class III Beta-Tubulin Isotype (hβ4) and Microtubule-Associated Protein 2 (MAP2) by the Human Retinoblastoma Cell Line WERI-Rbl , 1990 .

[69]  A. Frankfurter,et al.  The expression and posttranslational modification of a neuron-specific beta-tubulin isotype during chick embryogenesis. , 1990, Cell motility and the cytoskeleton.

[70]  V P Collins,et al.  Neuroblastic differentiation potential of the human retinoblastoma cell lines Y-79 and WERI-Rb1 maintained in an organ culture system. An immunohistochemical, electron microscopic, and biochemical study. , 1989, The American journal of pathology.

[71]  K. Sullivan.  Structure and utilization of tubulin isotypes. , 1988, Annual review of cell biology.